主页 > 生命科学 >
【drug-news】Medicines 公司药物有助于控制血压
Medicines Co. drug helps tame blood pressure
NEW ORLEANS (Reuters) - An experimental treatment developed by Medicines Co. did a better job controlling blood pressure during surgery than some standard treatments, according to two studies released on Tuesday.
Researchers compared the investigational therapy, called clevidipine or Cleviprex, with a standard cocktail of drug treatments in three separate studies. In two of the trials, the Medicines Co. drug was statistically better at keeping blood pressure in check.
The results were released at the American College of Cardiology annual meeting in New Orleans, which is concluding on Tuesday.
Medicines Co. expects to file its application with the U.S. Food and Drug Administration by the end of the second quarter.
The three trials, which involved a total of 1,964 heart surgery patients, also found no statistical differences in death, heart attack, stroke or kidney problems in the patients getting the experimental drug, vs. those getting conventional treatments.
The intravenously-given drug acts by relaxing smooth muscle cells lining small arteries, which expands the arteries and reduces blood pressure.
Medicines Co. shares were down 30 cents, or 1.2 percent, at $25.05 in afternoon Nasdaq trading. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Medicines Co. drug helps tame blood pressure
Medicines 公司的药物有助于控制血压
NEW ORLEANS (Reuters) - An experimental treatment developed by Medicines Co. did a better job controlling blood pressure during surgery than some standard treatments, according to two studies released on Tuesday.
新奥尔良（路透社）—据周二发表的两项研究结果，由Medicines 公司开发的试验药物与某些标准治疗药物相比，能更好地控制手术期间的血压。
Researchers compared the investigational therapy, called clevidipine or Cleviprex, with a standard cocktail of drug treatments in three separate studies. In two of the trials, the Medicines Co. drug was statistically better at keeping blood pressure in check.
研究人员对试验药物氯维地平和标准的鸡尾酒药物疗法进行了三次独立的对照性研究。其中二次研究表明，Medicines公司的药物能更好地控制血压，其结果具有统计学意义。
The results were released at the American College of Cardiology annual meeting in New Orleans, which is concluding on Tuesday.
该结果周二在新奥尔良结束的美国心脏病学会年会上发表。
Medicines Co. expects to file its application with the U.S. Food and Drug Administration by the end of the second quarter.
Medicines公司希望在第二季度末向FDA提交申请文件。
The three trials, which involved a total of 1,964 heart surgery patients, also found no statistical differences in death, heart attack, stroke or kidney problems in the patients getting the experimental drug, vs. those getting conventional treatments.
共有1964名心脏手术患者参与了该三次试验，与接受常规药物治疗的患者比较，应用受试药物的患者在死亡、心脏病发作、中风或肾脏问题方面未见统计学差异。
The intravenously-given drug acts by relaxing smooth muscle cells lining small arteries, which expands the arteries and reduces blood pressure.
该药物经静脉给药，通过松弛小动脉内壁平滑肌细胞、扩张动脉从而减低血压。
Medicines Co. shares were down 30 cents, or 1.2 percent, at $25.05 in afternoon Nasdaq trading.
Medicines公司股票今天下午的Nasdaq交易中下跌30美分（跌幅1.2%），至25.05美元。
编译：
Medicines 公司的药物有助于控制血压
据路透社3月27日报道，由Medicines 公司开发的药物氯维地平与常规治疗药物相比，能更好地控制手术期间的血压。该结果是周二在新奥尔良结束的美国心脏病学会年会上发表的。
研究人员对试验药物氯维地平和标准的鸡尾酒药物疗法进行了三次独立的对照性研究。其中二次研究表明，Medicines公司的药物能更好地控制血压，其结果具有统计学意义。共有1964名心脏手术患者参与了该三次试验，与接受常规药物治疗的患者比较，应用受试药物的患者在死亡、心脏病发作、中风或肾脏问题方面未见统计学差异。该药物经静脉给药，通过松弛小动脉内壁平滑肌细胞、扩张动脉从而减低血压。
Medicines公司希望在第二季度末向FDA提交申请文件。
Medicines公司股票今天下午的Nasdaq交易中下跌30美分（跌幅1.2%），至25.05美元。
http://www.reuters.com/article/health-SP/idUSN2719816820070327
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-09-01 05:12
医学,生命科学网